Breast cancer · 19 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
AC-THP (Docetaxel, Phesgo) Variant #01 | ERBB2 | R 111 065 | 21d | — | — | — | — | — |
ddAC-THP (Paclitaxel, Phesgo) Variant #01 | ERBB2 | R 107 901 | 21d | — | — | — | — | — |
FEC-THP (Docetaxel) Variant #01 | ERBB2 | R 81 728 | 21d | — | — | — | — | 1 |
AC-THP (Docetaxel) Variant #01 | ERBB2 | R 80 034 | 21d | — | — | — | — | 1 |
ddAC-THP (Paclitaxel) Variant #01 | ERBB2 | R 76 894 | 21d | — | — | — | — | 1 |
Neratinib and Paclitaxel, then AC Variant #01 | ERBB2 | R 60 400 | 21d | — | — | — | — | — |
Neratinib and Paclitaxel, then ddAC Variant #01 | ERBB2 | R 60 400 | 21d | — | — | — | — | — |
AC-THL (Paclitaxel) Variant #01 | ERBB2 | R 34 640 | 28d | — | — | — | — | — |
AC-TL (Paclitaxel) Variant #01 | ERBB2 | R 33 780 | 28d | — | — | — | — | — |
ECH-TH (Docetaxel) Variant #01 | ERBB2 | R 19 771 | 21d | — | — | — | — | — |
EC-TH (Docetaxel) Variant #02 | ERBB2 | R 17 343 | 21d | — | — | — | — | 1 |
TH-FEC and H (Docetaxel) Variant #01 | ERBB2 | R 14 327 | 21d | — | — | — | — | — |
FEC-TH (Paclitaxel) Variant #01 | ERBB2 | R 13 922 | 21d | — | — | — | — | 1 |
TH-FEC and H (Paclitaxel) Variant #01 | ERBB2 | R 13 887 | 21d | — | — | — | — | — |
AC-TH (Paclitaxel) Variant #01 | ERBB2 | R 12 820 | 21d | — | — | — | — | 3 |
TH-AC (Paclitaxel) Variant #01 | ERBB2 | R 12 820 | 21d | — | — | — | — | — |
TH-ddAC (Paclitaxel) Variant #01 | ERBB2 | R 12 820 | 21d | — | — | — | — | — |
TH-FEC and H (Docetaxel, SC Trastuzumab) Variant #01 | ERBB2 | R 3 889 | 21d | — | — | — | — | — |
T-FEC Variant #01 | ERBB2 | R 3 449 | 21d | — | — | — | — | — |
19 of 19 regimens shown